DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 17555/S-068, S-056 and S-071
NDA 19856/S-024, S-016 and S-028

SUPPLEMENT APPROVAL

Merck Sharp & Dohme Corp.
Attention: Roy Williams
Senior Scientist, Regulatory Affairs
351 North Sumneytown Pike, PO Box 1000
North Wales, PA 19454-2505

Dear Mr. Williams:

Please refer to your Supplemental New Drug Applications (sNDAs) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for the following:

Application	Drug Product	Submitted on:	Received on:
NDA 17555/S-068 NDA 19856/S-024	Sinemet (carbidopa/levodopa) Tablets Sinemet CR (carbidopa/levodopa) Tablets	1/26/2007	1/29/2007
NDA 17555/S-056 NDA 19856/S-016	Sinemet (carbidopa/levodopa) Tablets Sinemet CR (carbidopa/levodopa) Tablets	2/22/2013	2/22/2013
NDA 17555/S-071 NDA 19856/S-028	Sinemet (carbidopa/levodopa) Tablets Sinemet CR (carbidopa/levodopa) Tablets	9/20/2013	9/20/2013
These supplements provide for:			
NDA 17555/S-068 NDA 19856/S-024	"Changes Being Effected" Precautions: General - adds somnolence and sudden onset of sleep. Precautions: Nursing Mothers - evidence of L-dopa in breast milk.		
NDA 17555/S-056 NDA 19856/S-016	"Prior Approval Supplements" Response to 12/18/02 AE letter: Addition of Geriatric Use subsection under PRECAUTIONS and the addition of a Drug Abuse and Dependency subsection under ADVERSE REACTIONS sections of these product labels.		
NDA 17555/S-071 NDA 19856/S-028	"Changes Being Effected" Revised to include drug interactions with dopamine-depleting agents or other drugs known to deplete monoamine stores in the CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS sections.		

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf. Information and Instructions for completing the form can be found at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, call Stacy Metz, Senior Regulatory Project Manager, at (301) 796-2139.

Sincerely,

{See appended electronic signature page}

Eric Bastings, MD
Deputy Director
Division of Neurology Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ERIC P BASTINGS
07/17/2014